BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2890401)

  • 1. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
    Dearden CE; Matutes E; Hoffbrand AV; Ganeshaguru K; Brozovic M; Williams HJ; Traub N; Mills M; Linch DC; Catovsky D
    Br Med J (Clin Res Ed); 1987 Oct; 295(6603):873-5. PubMed ID: 2890401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
    Daenen S; Rojer RA; Smit JW; Halie MR; Nieweg HO
    Br J Haematol; 1984 Dec; 58(4):723-7. PubMed ID: 6097297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxycoformycin in therapy of refractory lymphoid neoplasms.
    Ho AD; Thaler J; Kuse R; Willemze R; Mandelli F; Lauria F; Zittoun R; Stryckmans P
    Onkologie; 1988 Feb; 11(1):35-7. PubMed ID: 3283623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to deoxycoformycin in mature T cell malignancies.
    Ho AD; Stryckmans P; Zittoun R
    Br Med J (Clin Res Ed); 1987 Dec; 295(6611):1483-4. PubMed ID: 3500754
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia.
    el'Agnaf MR; Ennis KE; Morris TC; Robertson JH; Markey G; Alexander HD
    Br J Haematol; 1986 May; 63(1):93-104. PubMed ID: 2939873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell chronic lymphocytic leukaemia: anomalous cell markers, variable morphology, and marked responsiveness to pentostatin (2'-deoxycoformycin).
    Spiers AS; Davis MP; Levine M; Li CY; Mangan KF; Mazza JJ; Neu LT; O'Brien J; Rauch AE; Wiltsie JC
    Scand J Haematol; 1985 Jan; 34(1):57-67. PubMed ID: 2578689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug.
    O'Dwyer PJ; Wagner B; Leyland-Jones B; Wittes RE; Cheson BD; Hoth DF
    Ann Intern Med; 1988 May; 108(5):733-43. PubMed ID: 3282467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
    Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycoformycin in the treatment of leukemias and lymphomas.
    Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
    Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
    Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
    Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cutaneous T cell lymphoma with 2'-deoxycoformycin (pentostatin).
    Dang-Vu AP; Olsen EA; Vollmer RT; Greenberg ML; Hershfield MS
    J Am Acad Dermatol; 1988 Oct; 19(4):692-8. PubMed ID: 3263401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.
    Yamaguchi K; Yul LS; Oda T; Maeda Y; Ishii M; Fujita K; Kagiyama S; Nagai K; Suzuki H; Takatsuki K
    Leuk Res; 1986; 10(8):989-93. PubMed ID: 3489140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxycoformycin in the treatment of mature T-cell leukaemias.
    Dearden C; Matutes E; Catovsky D
    Br J Cancer; 1991 Nov; 64(5):903-6. PubMed ID: 1931613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deoxycoformycin.
    Brito-Babapulle F; Huang D; Lavender P; Galton D; Catovsky D
    Eur J Haematol; 1988 Feb; 40(2):185-7. PubMed ID: 3257929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to deoxycoformycin in T cell leukaemias.
    Catovsky D; Dearden C
    Br Med J (Clin Res Ed); 1988 Jan; 296(6618):356. PubMed ID: 2894233
    [No Abstract]   [Full Text] [Related]  

  • 17. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 18. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
    Spiers AS
    Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
    Dearden CE; Matutes E; Catovsky D
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.
    Spiers AS; Ruckdeschel JC; Horton J
    Scand J Haematol; 1984 Feb; 32(2):130-4. PubMed ID: 6608139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.